|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Binefa G, Rodriguez-Moranta F, Teule A and
Medina-Hayas M: Colorectal cancer: From prevention to personalized
medicine. World J Gastroenterol. 20:6786–6808. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim SE, Paik HY, Yoon H, Lee JE, Kim N and
Sung MK: Sex- and gender-specific disparities in colorectal cancer
risk. World J Gastroenterol. 21:5167–5175. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Woolston A, Khan K, Spain G, Barber LJ,
Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M, Patil Y,
Newey A, et al: Genomic and transcriptomic determinants of therapy
resistance and immune landscape evolution during Anti-EGFR
treatment in colorectal cancer. Cancer Cell. 36:35–50, e9. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Marjaneh RM, Khazaei M, Ferns GA, Avan A
and Aghaee-Bakhtiari SH: The role of microRNAs in 5-FU resistance
of colorectal cancer: Possible mechanisms. J Cell Physiol.
234:2306–2316. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wei L, Wang X, Lv L, Liu J, Xing H, Song
Y, Xie M, Lei T, Zhang N and Yang M: The emerging role of microRNAs
and long noncoding RNAs in drug resistance of hepatocellular
carcinoma. Mol Cancer. 18:1472019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xiong G, Liu C, Yang G, Feng M, Xu J, Zhao
F, You L, Zhou L, Zheng L, Hu Y, et al: Long noncoding RNA GSTM3TV2
upregulates LAT2 and OLR1 by competitively sponging let-7 to
promote gemcitabine resistance in pancreatic cancer. J Hematol
Oncol. 12:972019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Martens-Uzunova ES, Bottcher R, Croce CM,
Jenster G, Visakorpi T and Calin GA: Long noncoding RNA in
prostate, bladder, and kidney cancer. Eur Urol. 65:1140–1151. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ni W, Yao S, Zhou Y, Liu Y, Huang P, Zhou
A, Liu J, Che L and Li J: Long noncoding RNA GAS5 inhibits
progression of colorectal cancer by interacting with and triggering
YAP phosphorylation and degradation and is negatively regulated by
the m6A reader YTHDF3. Mol Cancer. 18:1432019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fu D, Lu C, Qu X, Li P, Chen K, Shan L and
Zhu X: LncRNA TTN-AS1 regulates osteosarcoma cell apoptosis and
drug resistance via the miR-134-5p/MBTD1 axis. Aging (Albany NY).
11:8374–8385. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fang Z, Zhao J, Xie W, Sun Q, Wang H and
Qiao B: LncRNA UCA1 promotes proliferation and cisplatin resistance
of oral squamous cell carcinoma by sunppressing miR-184 expression.
Cancer Med. 6:2897–2908. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang P, Xu J, Wang Y and Cao X: An
interferon-independent lncRNA promotes viral replication by
modulating cellular metabolism. Science. 358:1051–1055. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang J, Yin M, Peng G and Zhao Y: CRNDE:
An important oncogenic long non-coding RNA in human cancers. Cell
Prolif. 51:e124402018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Han P, Li JW, Zhang BM, Lv JC, Li YM, Gu
XY, Yu ZW, Jia YH, Bai XF, Li L, et al: The lncRNA CRNDE promotes
colorectal cancer cell proliferation and chemoresistance via
miR-181a-5p-mediated regulation of Wnt/β-catenin signaling. Mol
Cancer. 16:92017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ji D, Jiang C, Zhang L, Liang N, Jiang T,
Yang B and Liang H: LncRNA CRNDE promotes hepatocellular carcinoma
cell proliferation, invasion, and migration through regulating
miR-203/BCAT1 axis. J Cell Physiol. 234:6548–6560. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jing H, Xia H, Qian M and Lv X: Long
noncoding RNA CRNDE promotes non-small cell lung cancer progression
via sponging microRNA-338-3p. Biomed Pharmacother. 110:825–833.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liang C, Zhang B, Ge H, Xu Y, Li G and Wu
J: Long non-coding RNA CRNDE as a potential prognostic biomarker in
solid tumors: A meta-analysis. Clin Chim Acta. 481:99–107. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ding C, Han F, Xiang H, Xia X, Wang Y, Dou
M, Zheng J, Li Y, Xue W, Ding X and Tian P: LncRNA CRNDE is a
biomarker for clinical progression and poor prognosis in clear cell
renal cell carcinoma. J Cell Biochem. 119:10406–10414. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang HY, Huang CP, Cao MM, Wang YF and Liu
Y: Long non-coding RNA CRNDE may be associated with poor prognosis
by promoting proliferation and inhibiting apoptosis of cervical
cancer cells through targeting PI3K/AKT. Neoplasma. 65:872–880.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun XH, Fan WJ, An ZJ and Sun Y:
Inhibition of long noncoding RNA CRNDE increases chemosensitivity
of medulloblastoma cells by targeting miR-29c-3p. Oncol Res.
28:95–102. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ding J, Li J, Wang H, Tian Y, Xie M, He X,
Ji H, Ma Z, Hui B, Wang K and Ji G: Long noncoding RNA CRNDE
promotes colorectal cancer cell proliferation via epigenetically
silencing DUSP5/CDKN1A expression. Cell Death Dis. 8:e29972017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun F, Liang W and Qian J: The
identification of CRNDE, H19, UCA1 and HOTAIR as the key lncRNAs
involved in oxaliplatin or irinotecan resistance in the
chemotherapy of colorectal cancer based on integrative
bioinformatics analysis. Mol Med Rep. 20:3583–3596. 2019.PubMed/NCBI
|
|
25
|
Gao H, Song X, Kang T, Yan B, Feng L, Gao
L, Ai L, Liu X, Yu J and Li H: Long noncoding RNA CRNDE functions
as a competing endogenous RNA to promote metastasis and oxaliplatin
resistance by sponging miR-136 in colorectal cancer. Onco Targets
Ther. 10:205–216. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wiese EK and Hitosugi T: Tyrosine Kinase
signaling in cancer metabolism: PKM2 Paradox in the Warburg Effect.
Front Cell Dev Biol. 6:792018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li L, Liang Y, Kang L, Liu Y, Gao S, Chen
S, Li Y, You W, Dong Q, Hong T, et al: Transcriptional regulation
of the warburg effect in cancer by SIX1. Cancer Cell.
33:368–385.e7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li J, Cheng D, Zhu M, Yu H, Pan Z, Liu L,
Geng Q, Pan H, Yan M and Yao M: OTUB2 stabilizes U2AF2 to promote
the Warburg effect and tumorigenesis via the AKT/mTOR signaling
pathway in non-small cell lung cancer. Theranostics. 9:179–195.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang Z and Chen W: Long non-coding RNA
CRNDE promote the progression of tongue squamous cell carcinoma
through regulating the PI3K/AKT/mTOR signaling pathway. RSC Adv.
9:21381–21390. 2019. View Article : Google Scholar
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lunt SY and Vander Heiden MG: Aerobic
glycolysis: Meeting the metabolic requirements of cell
proliferation. Annu Rev Cell Dev Biol. 27:441–464. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vaupel P, Schmidberger H and Mayer A: The
Warburg effect: Essential part of metabolic reprogramming and
central contributor to cancer progression. Int J Radiat Biol.
95:912–919. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brooks GA: Cell-cell and intracellular
lactate shuttles. J Physiol. 587((Pt 23)): 5591–5600. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Held-Warmkessel J and Dell DD: Lactic
acidosis in patients with cancer. Clin J Oncol Nurs. 18:592–594.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Peppicelli S, Bianchini F and Calorini L:
Extracellular acidity, a ‘reappreciated’ trait of tumor environment
driving malignancy: Perspectives in diagnosis and therapy. Cancer
Metastasis Rev. 33:823–832. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shiraishi T, Verdone JE, Huang J, Kahlert
UD, Hernandez JR, Torga G, Zarif JC, Epstein T, Gatenby R,
McCartney A, et al: Glycolysis is the primary bioenergetic pathway
for cell motility and cytoskeletal remodeling in human prostate and
breast cancer cells. Oncotarget. 6:130–143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Holman GD: Chemical biology probes of
mammalian GLUT structure and function. Biochem J. 475:3511–3534.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Al-Azzam N: Sirtuin 6 and metabolic genes
interplay in Warburg effect in cancers. J Clin Biochem Nutr.
66:169–175. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hong X, Zhong L, Xie Y, Zheng K, Pang J,
Li Y, Yang Y, Xu X, Mi P, Cao H, et al: Matrine reverses the
warburg effect and suppresses colon cancer cell growth via
negatively regulating HIF-1α. Front Pharmacol. 10:14372019.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yu W, Yang Z, Huang R, Min Z and Ye M:
SIRT6 promotes the Warburg effect of papillary thyroid cancer cell
BCPAP through reactive oxygen species. Onco Targets Ther.
12:2861–2868. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lu Z, Guo Y, Zhang X, Li J, Li L, Zhang S
and Shan C: ORY-1001 Suppresses cell growth and induces apoptosis
in lung cancer through triggering HK2 mediated warburg effect.
Front Pharmacol. 9:14112018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lin G, Wu Y, Cai F, Li Z, Su S, Wang J,
Cao J and Ma L: Matrine promotes human myeloid leukemia cells
apoptosis through warburg effect mediated by hexokinase 2. Front
Pharmacol. 10:10692019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang S, Zhang Y, Cai Q, Ma M, Jin LY, Weng
M, Zhou D, Tang Z, Wang JD and Quan Z: Circular RNA FOXP1 promotes
tumor progression and Warburg effect in gallbladder cancer by
regulating PKLR expression. Mol Cancer. 18:1452019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Icard P, Shulman S, Farhat D, Steyaert JM,
Alifano M and Lincet H: How the Warburg effect supports
aggressiveness and drug resistance of cancer cells? Drug Resist
Updat. 38:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lu Z, Shi X, Gong F, Li S, Wang Y, Ren Y,
Zhang M, Yu B, Li Y, Zhao W, et al: RICTOR/mTORC2 affects
tumorigenesis and therapeutic efficacy of mTOR inhibitors in
esophageal squamous cell carcinoma. Acta Pharm Sin B. 10:1004–1019.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen GQ, Tang CF, Shi XK, Lin CY, Fatima
S, Pan XH, Yang DJ, Zhang G, Lu AP, Lin SH and Bian ZX:
Halofuginone inhibits colorectal cancer growth through suppression
of Akt/mTORC1 signaling and glucose metabolism. Oncotarget.
6:24148–24162. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sun Q, Chen X, Ma J, Peng H, Wang F, Zha
X, Wang Y, Jing Y, Yang H, Chen R, et al: Mammalian target of
rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is
critical for aerobic glycolysis and tumor growth. Proc Natl Acad
Sci USA. 108:4129–4134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Duvel K, Yecies JL, Menon S, Raman P,
Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S,
et al: Activation of a metabolic gene regulatory network downstream
of mTOR complex 1. Mol Cell. 39:171–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yalcin S, Marinkovic D, Mungamuri SK,
Zhang X, Tong W, Sellers R and Ghaffari S: ROS-mediated
amplification of AKT/mTOR signalling pathway leads to
myeloproliferative syndrome in Foxo3(−/-) mice. EMBO J.
29:4118–4131. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Maiese K, Chong ZZ, Shang YC and Wang S:
mTOR: On target for novel therapeutic strategies in the nervous
system. Trends Mol Med. 19:51–60. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Siska PJ, van der Windt GJ, Kishton RJ,
Cohen S, Eisner W, MacIver NJ, Kater AP, Weinberg JB and Rathmell
JC: Suppression of glut1 and glucose metabolism by decreased
Akt/mTORC1 signaling drives T cell impairment in B cell leukemia. J
Immunol. 197:2532–2540. 2016. View Article : Google Scholar : PubMed/NCBI
|
